Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Meredith Quarles

Physician Assistant, Medical Appomattox, VA Physician Assistant

NPI 1104225101 CMS profile 10572021

131 Jones St, Appomattox, VA 24522

Open in the dashboard

General payments

$10,834

728 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Meredith Quarles of Appomattox, VA is reported in the CMS Open Payments database as having received $10,834 across 728 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,213 65
2024 General $1,857 107
2023 General $2,386 165
2022 General $2,429 195
2021 General $2,950 196

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Quarles
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Meredith Quarles were reported at $1,213. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Meredith Quarles Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,950 $156 $41–$563 $132
2022 $2,429 $185 $55–$649 $149
2023 $2,386 $199 $58–$717 $160
2024 $1,857 $206 $62–$740 $164
2025 $1,213 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,060 133 payments
  2. AbbVie, Inc. $1,893 152 payments
  3. AstraZeneca Pharmaceuticals LP $1,243 38 payments
  4. Pfizer Inc. $942 87 payments
  5. Lilly USA, LLC $846 47 payments
  6. Janssen Pharmaceuticals, Inc $530 42 payments
  7. Amgen Inc. $425 31 payments
  8. Abbott Laboratories $413 20 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $304 21 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $295 37 payments
  11. Other $1,882 120 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,827 727 payments
  2. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,110 80 payments
  2. Ozempic $975 74 payments
  3. FARXIGA $949 25 payments
  4. RYBELSUS $945 73 payments
  5. QULIPTA $632 45 payments
  6. NURTEC ODT Pain $617 60 payments
  7. BREZTRI $565 7 payments
  8. NURTEC ODT Primary Care $542 52 payments
  9. XARELTO $530 42 payments
  10. Wegovy $440 23 payments
  11. Other $7,663 557 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

7,736

Median for Physician Assistant: 241

Drug cost

$814,958

Median for Physician Assistant: $4,110

Branded share of claims

22.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 105 $124,778
Ozempic Semaglutide Brand 78 $95,166
Eliquis Apixaban Brand 91 $79,602
Mounjaro Tirzepatide Brand 46 $48,116
Rybelsus Semaglutide Brand 21 $43,037
Januvia Sitagliptin Phosphate Brand 31 $38,138
Trulicity Dulaglutide Brand 26 $33,650
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 51 $31,876
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 39 $28,432
Farxiga Dapagliflozin Propanediol Brand 28 $27,572

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 110 billing codes

Paid by Medicare

$178,785

Of which drugs: $73,064

Medicare patients

418

Average age 74

Services billed

10,622

262 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 50%
Arthritis 38%
Diabetes 34%
Depression 26%
Atrial fibrillation 19%
Ischemic heart disease 17%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 13 1,080 $21,965
Pcv20 vaccine im 90677 Office 35 35 $10,122
Vaccine for influenza for injection into muscle 90662 Office 80 83 $6,672

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $144
$144 — —
UBRELVY
  • AbbVie, Inc. $137
$137 — —
Wegovy
  • Novo Nordisk Inc $117
$117 — —
MOUNJARO
  • Lilly USA, LLC $107
$107 46 —
JARDIANCE
  • Lilly USA, LLC $69
  • Boehringer Ingelheim Pharmaceuticals, Inc. $37
$105 105 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

728 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record